Nanomedicine in cancer immunotherapy /
Nanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often personalized to the patient. The book covers a wide range of nanomaterial types for use in cancer immunotherapy, including hydrogel,...
Sparad:
| Övriga upphovsmän: | |
|---|---|
| Materialtyp: | Elektronisk E-bok |
| Språk: | engelska |
| Publicerad: |
London, United Kingdom :
Academic Press,
2024.
|
| Ämnen: | |
| Länkar: | ScienceDirect |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | on1422015383 | ||
| 003 | OCoLC | ||
| 005 | 20260915095235.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 240214s2024 enk o 001 0 eng d | ||
| 040 | |a OPELS |b eng |e rda |e pn |c OPELS |d OCLCO |d OCLKB |d OCLCL |d SFB |d YDX |d OCLCF |d OCLCO | ||
| 019 | |a 1420742904 |a 1427624065 | ||
| 020 | |z 9780443187704 | ||
| 020 | |a 0443187703 | ||
| 020 | |a 9780443187704 | ||
| 020 | |a 9780443187711 |q (electronic bk.) | ||
| 020 | |a 0443187711 |q (electronic bk.) | ||
| 035 | |a (OCoLC)1422015383 |z (OCoLC)1420742904 |z (OCoLC)1427624065 | ||
| 050 | 4 | |a RC271.I45 |b N36 2024eb | |
| 060 | 4 | |a QZ 266 | |
| 082 | 0 | 4 | |a 616.99/4061 |2 23/eng/20240214 |1 https://id.oclc.org/worldcat/ddc/E3xHPfT4KgyfbFF6fKcRyx6WPM |
| 245 | 0 | 0 | |a Nanomedicine in cancer immunotherapy / |c edited by Prashant Kesharwani. |
| 264 | 1 | |a London, United Kingdom : |b Academic Press, |c 2024. | |
| 300 | |a 1 online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a Nanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often personalized to the patient. The book covers a wide range of nanomaterial types for use in cancer immunotherapy, including hydrogel, lipid, exosome, gold and peptide nanoparticles. The preparation, application, pros and cons of each nanomaterial class is reviewed, helping the reader understand the potential for each to tailor their own selections. Nanovaccines are also covered, along with a clinical evaluation and market analysis of nanomedicines for immunotherapy, offering an important clinical and commercial overview of this rapidly developing field. This book is an interesting reference for those working in the fields of nanotechnology, immunology, and cancer therapeutics, as well as clinicians with an interest in novel nano-based cancer treatments. | ||
| 500 | |a Includes index. | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Front Cover -- Nanomedicine in Cancer Immunotherapy -- Copyright Page -- Dedication -- Contents -- List of contributors -- About the editor -- Preface -- Acknowledgments -- 1 Immunoadjuvants for cancer immunotherapy -- 1.1 Why adjuvants for cancer immunotherapy? -- 1.2 Nanostructures for cancer immunotherapy -- 1.3 Viruses against cancer -- 1.4 Combined approaches for immunotherapy against cancer -- 1.5 Emerging cationic nanoadjuvants for cancer immunotherapy -- Acknowledgments -- References -- 2 Nanotechnology as an emerging option in cancer immunotherapy -- 2.1 Introduction -- 2.2 Traditional methods used in cancer treatment -- 2.2.1 Surgery -- 2.2.2 Chemotherapy -- 2.2.3 Radiotherapy -- 2.3 Cancer immunotherapy -- 2.3.1 Disadvantages of cancer immunotherapies -- 2.3.1.1 Variability in the immune response -- 2.3.1.2 Growing resistance to immunotherapies -- 2.3.1.3 Problems derived from the immune system -- 2.4 Different adoptive cellular transfer immunotherapies strategies for cancer -- 2.4.1 Tumor infiltrating lymphocytes -- 2.4.2 Cytokine-induced killer cells -- 2.4.3 T-cell receptor -- 2.4.4 Chimeric antigen receptor T cells -- 2.5 Nanotechnology-associated cancer immunotherapy strategies -- 2.6 Types of nanoparticles used in cancer immunotherapy -- 2.6.1 Polymeric nanoparticles -- 2.6.2 Lipid-based nanoparticles -- 2.6.3 Inorganic nanoparticles -- 2.6.4 Some examples of the types above of nanoparticles -- 2.6.4.1 Liposomes -- 2.6.4.2 Gold nanoparticles -- 2.6.4.3 PLGA nanoparticles -- 2.7 The targeted delivery of nanoparticles with cancer immunotherapy -- 2.7.1 Targeting immunological cells with nanoparticles -- 2.7.2 Antigen intracellular delivery -- 2.8 Direct immune checkpoint inhibition with nanoparticles -- 2.8.1 PD-L1 -- 2.8.2 CTLA-4 -- 2.8.3 Resistance to immune checkpoint blockage. | |
| 505 | 8 | |a 2.8.4 Effect of physicochemical properties on vaccine nanocarriers design -- 2.8.5 Nanoparticles as a carrier of mRNA cancer vaccine -- 2.9 Conclusion -- References -- Further reading -- 3 Different administration routes for nanovectors in cancer immunotherapy -- 3.1 Introduction -- 3.2 Types of nanovectors used in cancer immunotherapy -- 3.3 Deficiencies in delivery and efficacy of nanovectors -- 3.4 Nanovectors targeting mechanisms -- 3.4.1 Passive targeting -- 3.4.2 Active targeting -- 3.5 Nanovectors' administration routes -- 3.6 Transdermal delivery -- 3.6.1 Molecular size -- 3.6.2 Affinities -- 3.6.3 Solubility -- 3.6.4 Ionization -- 3.7 Subcutaneous delivery -- 3.8 IV delivery -- 3.9 Oral delivery -- 3.10 Inhalation (pulmonary) delivery -- 3.11 Intramuscular delivery -- 3.12 Intraperitoneal delivery -- 3.13 Intranasal delivery -- 3.14 Rectal delivery -- 3.15 Vaginal delivery -- 3.16 IT delivery -- 3.17 Conclusion and future prospects -- References -- 4 Two-dimensional material-based nanomedicines for cancer immunotherapy -- 4.1 Introduction -- 4.2 Main 2D materials and their applications in cancer immunotherapy -- 4.2.1 Graphene and its derivatives -- 4.2.1.1 Properties and preparation methods of graphene and its analogs -- 4.2.1.2 The applications of graphene and its analogs in cancer immunotherapy -- 4.2.2 Black phosphorus -- 4.2.2.1 Properties and preparation methods of black phosphorus -- 4.2.2.2 The applications of black phosphorus in cancer immunotherapy -- 4.2.3 Transition metal chalcogenides -- 4.2.3.1 Properties and preparation methods of transition metal chalcogenides -- 4.2.3.2 The applications of transition metal chalcogenides in cancer immunotherapy -- 4.2.4 2D carbides and nitrides (MXenes) -- 4.2.4.1 Properties and preparation methods of MXenes -- 4.2.4.2 The applications of MXenes in cancer immunotherapy. | |
| 505 | 8 | |a 4.2.5 Other 2D materials -- 4.3 Summary and perspectives -- Acknowledgments -- Conflicts of interest -- References -- 5 Hydrogel-based nanomedicines for cancer immunotherapy -- 5.1 Introduction -- 5.1.1 Cancer -- 5.1.2 Cancer immunotherapy -- 5.2 Nanotechnology and nanomedicine -- 5.2.1 Diagnostics -- 5.2.2 Regenerative medicine -- 5.2.3 Drug delivery -- 5.3 Role of nanotechnology in cancer immunotherapy -- 5.4 Nanomaterials -- 5.5 Hydrogels -- 5.5.1 Classification of hydrogels -- 5.5.1.1 Natural, synthetic, or semi-synthetic (hybrid) hydrogels -- 5.5.1.2 Homopolymers, copolymers, interpenetrating networks (IPNs), and semi-IPNs hydrogels -- 5.5.1.3 Chemical and physical hydrogels -- 5.5.1.4 Nonionic, anionic, cationic, and ampholytic hydrogels -- 5.5.1.5 Macroscopic gels, microgels, and nanogels -- 5.5.1.6 Amorphous, crystalline, and semi-crystalline hydrogels -- 5.5.1.7 Smart hydrogels -- 5.6 Hydrogel-based approaches in cancer immunotherapy -- 5.6.1 Delivery -- 5.6.1.1 Delivery of small molecules -- 5.6.1.2 Delivery of macromolecular drugs -- 5.6.1.3 Codelivery of immunotherapeutic agents -- 5.6.1.4 Immune cell delivery -- 5.6.2 Vaccines -- 5.6.3 Chemotherapy-combinational immunotherapy -- 5.6.4 Cellular immunotherapy -- 5.6.5 Inflammation modulation -- 5.6.6 Phototherapy-combinational immunotherapy -- 5.7 Conclusion and future perspective -- References -- 6 Exosomes-based nanomedicines for cancer immunotherapy -- 6.1 Introduction -- 6.1.1 Cancer and nanotechnology -- 6.1.2 Current challenges to cancer nanomedicines and possible adaptations -- 6.2 Exosomes for cancer immunotherapy -- 6.2.1 Exosomes for treatment of lung cancer (LC) -- 6.2.2 Exosomes for treatment of cervical cancer -- 6.2.3 Exosomes for treatment of breast cancer -- 6.3 Summary -- Acknowledgment -- Conflict of interest -- References. | |
| 505 | 8 | |a 7 Lipid-based nanomedicines for cancer immunotherapy -- 7.1 Introduction -- 7.2 Cancer immunotherapy -- 7.3 Immunotherapeutic delivery systems -- 7.4 Different kinds of nanocarriers that are based on lipids -- 7.4.1 Solid lipid nanoparticles (SLNs) -- 7.4.2 Nanostructured lipid carriers (NLC) -- 7.4.3 Liposome -- 7.4.4 Niosomes -- 7.5 Oral lipid nanomedicines -- 7.6 Conclusions -- References -- 8 Inorganic nanoparticle-based nanomedicines for cancer immunotherapy -- 8.1 Introduction of cancer immunotherapy -- 8.2 Advantages of inorganic nanomaterials -- 8.3 Silica nanomaterials for immunotherapy -- 8.4 Gold-nanomaterials for immunotherapy -- 8.5 Copper-nanomaterials for immunotherapy -- 8.6 Magnetic nanomaterials for immunotherapy -- 8.7 Carbon-nanomaterials for immunotherapy -- 8.8 Quantum dots for immunotherapy -- 8.9 Conclusion and perspective -- Acknowledgments -- Conflict of interests -- References -- Further reading -- 9 Liposome-based nanomedicines for cancer immunotherapy -- 9.1 Introduction -- 9.2 Cancer immunotherapy -- 9.2.1 Tumor-specific cellular immunotherapy -- 9.2.2 Adoptive cellular immunotherapy -- 9.2.3 NK-cell therapy -- 9.2.4 CAR-T cell immunotherapy -- 9.3 Nanomedicine in cancer immunotherapy -- 9.4 Liposomes: an overview -- 9.4.1 Conventional liposomes -- 9.4.2 Cholesterol-conjugated liposomes -- 9.4.3 pH-sensitive liposomes -- 9.4.4 PEGylated or stealth liposomes -- 9.4.5 Ligand-targeted liposomes -- 9.4.6 Immunoliposomes -- 9.4.7 Multifunctional liposomes -- 9.5 Liposomes in cancer immunotherapy -- 9.5.1 Liposome-based active targeting in cancer immunotherapy -- 9.5.2 Liposome-based passive targeting in cancer immunotherapy -- 9.6 Challenges and future prospects -- 9.7 Conclusion -- Acknowledgement -- Conflict of interest -- References -- 10 Biomembrane-based nanoparticles for cancer immunotherapy. | |
| 505 | 8 | |a 10.1 Red blood cell membrane-based nanoparticles -- 10.2 White blood cell membrane-based nanoparticles -- 10.3 Platelet membrane-based nanoparticles -- 10.4 Mesenchymal stem cell membrane-based nanoparticles -- 10.5 Cancer cell membrane-based nanoparticles -- 10.6 Bacterial membrane-based nanoparticles -- 10.7 Hybrid biomembrane-based nanoparticles -- 10.8 Conclusion and outlook -- References -- 11 Dendrimer-based nanomedicines for cancer immunotherapy -- 11.1 Introduction -- 11.2 Synthesis and characterization of dendrimer nanoparticles -- 11.3 Dendrimers as general carriers for drug delivery -- 11.4 Dendrimer and enhancement of cancer immune responses -- 11.5 Dendrimers as vehicles for cancer immunotherapy -- 11.5.1 Cytokine-based immunotherapy -- 11.5.2 Vaccines -- 11.5.3 Monoclonal antibody-based therapy -- 11.5.4 Immune checkpoint inhibitors (ICIs)-based therapy -- 11.6 Dendrimer-based drug carriers in different cancers -- 11.7 Conclusions and future perspectives -- References -- 12 Magnetic nanocarriers for cancer immunotherapy -- 12.1 Cancer immunotherapy -- 12.2 Magnetic nanocarriers -- 12.3 Magnetic nanocarrier for cancer immunotherapy -- 12.3.1 Physicochemical properties of magnetic nanocarrier and cancer immunotherapy -- 12.3.1.1 Effects of magnetic nanocarrier size on cancer immunotherapy -- 12.3.1.2 Effects of magnetic nanocarrier shape on cancer immunotherapy -- 12.3.1.3 Effects of magnetic nanocarrier surface charge on cancer immunotherapy -- 12.3.2 Surface functionalization of magnetic nanocarrier for cancer immunotherapy -- 12.3.2.1 Cell membrane-coated magnetic nanocarrier for cancer immunotherapy -- 12.4 Definition of hyperthermia -- 12.4.1 Magnetic hyperthermia -- 12.4.2 Magnetic hyperthermia and cancer immunotherapy -- 12.5 Magnetic vaccination -- 12.6 Magnetic nanoparticle nanotheranostics -- 12.7 Conclusion -- References. | |
| 504 | |a Includes bibliographical references and index. | ||
| 650 | 0 | |a Cancer |x Immunotherapy. | |
| 650 | 0 | |a Nanomedicine. | |
| 650 | 0 | |a Drug delivery systems. | |
| 650 | 0 | |a Immunotherapy. | |
| 650 | 2 | |a Nanomedicine |0 (DNLM)D050997 | |
| 650 | 2 | |a Drug Delivery Systems |0 (DNLM)D016503 | |
| 650 | 2 | |a Immunotherapy |0 (DNLM)D007167 | |
| 650 | 6 | |a Cancer |x Immunothérapie. |0 (CaQQLa)201-0168739 | |
| 650 | 6 | |a Nanomédecine. |0 (CaQQLa)201-0448752 | |
| 650 | 6 | |a Systèmes d'administration de médicaments. |0 (CaQQLa)000260397 | |
| 650 | 6 | |a Immunothérapie. |0 (CaQQLa)201-0067406 | |
| 650 | 7 | |a Cancer |x Immunotherapy |2 fast |0 (OCoLC)fst00845386 | |
| 650 | 7 | |a Drug delivery systems |2 fast |0 (OCoLC)fst00898667 | |
| 650 | 7 | |a Immunotherapy |2 fast |0 (OCoLC)fst00968044 | |
| 650 | 7 | |a Nanomedicine |2 fast |0 (OCoLC)fst01744350 | |
| 700 | 1 | |a Kesharwani, Prashant, |e editor. |1 https://id.oclc.org/worldcat/entity/E39PCjMprrRPKDhgJDCyGwVqKm | |
| 776 | 0 | 8 | |i Print version: |t Nanomedicine in cancer immunotherapy. |d London, United Kingdom ; San Diego, CA : Academic Press, an imprint of Elsevier, [2024] |z 9780443187704 |w (OCoLC)1381294852 |
| 776 | 0 | 8 | |c Original |z 9780443187704 |z 0443187703 |w (OCoLC)1381294852 |
| 856 | 4 | 0 | |3 ScienceDirect |u https://www.sciencedirect.com/science/book/9780443187704 |